[2] Its molecular structure is uncommon for pharmacological compounds in that it has both an ozonide (trioxolane) group and an adamantane substituent.

[3][4] Initial results were disappointing, and in 2007 MMV withdrew support, after having invested $20M in the research;[5] Ranbaxy said at the time that it intended to continue developing arterolane in combination with another drug.

[1] In 2009, Ranbaxy started a Phase II clinical trial of arterolane in combination with piperaquine, and it was published in 2015.

[6][7] In 2012, Ranbaxy obtained approval to market an arterolane/piperaquine combination drug in India, under the brand name Synriam.

[5] In 2014, the product was also approved in Nigeria, Uganda, Senegal, Cameroon, Guinea, Kenya and Ivory Coast.